Anza Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus
- First Posted Date
- 2008-12-01
- Last Posted Date
- 2009-02-20
- Lead Sponsor
- Anza Therapeutics, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT00800007
- Locations
- 🇺🇸
Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸Alamo Medical Research, San Antonio, Texas, United States
Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment
Phase 1
Terminated
- Conditions
- Malignant Epithelial MesotheliomaAdenocarcinoma of the PancreasCarcinoma, Non-Small-Cell LungAdenocarcinoma of the Ovaries
- Interventions
- Biological: CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
- First Posted Date
- 2008-01-03
- Last Posted Date
- 2009-02-20
- Lead Sponsor
- Anza Therapeutics, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT00585845
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸National Cancer Institute, NCI, Bethesda, Maryland, United States
🇺🇸University of Pennsylvania Abramson Family Cancer Research Center, Philadelphia, Pennsylvania, United States
Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases
Phase 1
Completed
- Conditions
- Neoplasm MetastasisLiver NeoplasmsCarcinoma
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- Anza Therapeutics, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT00327652
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Mary Crowley Medical Research Center, Dallas, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath